DRKS00013604已完成不适用
Management of moderate to severe plaque psoriasis with Kyntheum® in daily practice - LIBERO
EO Pharma GmbH0 个研究点目标入组 668 人开始时间: 2017年12月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 668
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •1) Adult patients (= 18 years).
- •2) Patients must be a candidate for systemic therapy with Kyntheum® according to SmPC and local guidelines.
- •3) Decision to start treatment with Kyntheum® in a patient was taken before enrolment in the study.
- •4) Patients must have understood and voluntarily signed the ICF.
排除标准
- •1) Patients who are enrolled in any interventional clinical trial in parallel.
- •2) Patients who are already treated or have been previously treated with Kyntheum® before enrolment.
- •3) Patients, who did not sign the informed consent or incapacitated patients, who are not able to provide informed consent and/ or are under institutionalized care.
研究者
相似试验
进行中（未招募）
不适用
/AEUCTR2006-002523-16-SESynphora AB
撤回
4 期
Optimizing the treatment of psoriasis with methotrexate; after 40 years the first dose-finding study.psoriasis10014982NL-OMON37246Academisch Medisch Centrum80
已完成
不适用
A Pilot Study of Topical Honey for the Treatment of PsoriasisPsoriasisSkin - Dermatological conditionsACTRN12612000562875Medical Research Institute of New Zealand15
已完成
不适用
Management of psoriasis and risk and severity of COVID-19 infection in systemic, biologic and topical treatment for psoriasis during the COVID-19 pandemic: an epidemiological cohort studyPsoriasis1004743810014982NL-OMON51144Bravis Ziekenhuis1,500
已完成
不适用
A Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The 'APRAISAL' Study)Moderate Plaque PsoriasisNCT03059953Genesis Pharma S.A.302